Global Antiviral Drugs Market, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast To 2029

                                          
Global Antiviral Drugs Market 2021: By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others), By Type (Branded, Generic), By Application (HIV, Hepatitis, Herpes, Influenza, Others)

The Global Antiviral Drugs market size was valued at USD $37.27 Billion in 2020, USD $38.63 Billion in 2021, forecasted to reach  USD $40.03 Billion in 2022, and is projected to reach USD $53.73 Billion by 2030, and is anticipated to expand at a CAGR of 3.63% over the forecast period from 2020 to 2030.

Global Antiviral Drugs Market is an upcoming market research report by Trusted Business Insights. The report covers in-depth details of the evolving trends in the global antiviral drugs market. The data and information in the report are based on inputs from experts and in-depth market analysis within the specific industry and target market. It covers growth prospects and market landscape over the next 10 years, along with company details about the top 10 players in the target market. 

Overview

Antiviral drugs are medicines, which are used for treating viral infections such as human immunodeficiency virus (HIV), hepatitis, herpes, and influenza. Antiviral drugs are administered in the form of vaccines. Moreover, antiviral drugs are used for specific viral infections, except for a few, which are effective against a wide range of viruses. In addition, deferent investigational drugs for the treatment of human immunodeficiency virus infection are currently in the pipeline.

Dynamics

One among some of the major factors expected to drive growth of the antiviral drug market is increasing infections of HIV. Moreover, increasing prevalence of respiratory syncytial virus (RSV), influenza, and hepatitis are projected to drive increasing demand for antiviral drugs over the forecast period. According to WHO, 887,000 deaths happened in 2015 due to hepatitis B and around 257 million patients were living with the disease in 2015. Moreover, according to the Centre for Disease Control and Prevention (CDC), approximately 13 million influenza cases were reported in 2019. High cost involved in drug development, growth in the demand for alternative medicines, including homeopathy and naturopathy, drop in the price of U.S. Medicare, competitive dynamics, increasing awareness about the availability of vaccines, and other preventive measures are projected to restrain growth of the market over the forecast period. Growth opportunities in the emerging economies of Asia-Pacific and Latin America, Middle East & Africa (LAMEA) regions and development of broad-spectrum antibiotics are projected to create growth opportunities for key players in the market over the forecast period.

Global Antiviral Drugs Market Segment Analysis:

By Drug Class: Among the drug class segments, the reverse transcriptase inhibitors segment currently accounts for highest revenue share, and is projected to maintain its dominance over the next five years. This can be attributed to its effectiveness in preventing or slowing down viral infections.

BY Type: Among the type segments, the branded segment is projected to maintain dominance in terms of revenue share over the generic segment over the forecast period. This can be attributed to the belief among people that branded medicines are safer than generic medicines. Generic medicine is also projected to register significant growth in terms of revenue share, which is attributed to patent expiry of different branded products and increasing adoption in developing countries. Moreover, number of key players such as Aurobindo Pharma, Cipla Inc., and Dr. Reddys Laboratories Ltd. are focused on producing generic medicines at an affordable rate.

By Application: The hepatitis segment among the application segments is projected to account for comparatively higher revenue share over the forecast period. This can be attributed to increasing availability of antiviral drugs for treating hepatitis such as tenofovir, entecavir, telbivudine, lamivudine, and adefovir. In addition, increasing incidences of hepatitis is another factor projected to drive growth of the segment. The HIV segment is projected to be fastest-growing segment due to increasing prevalence of HIV.

Global Antiviral Drugs Market Regional Analysis:

The antiviral drugs market in North America is expected to dominate the market in terms of revenue share over the forecast period. This growth of the market in the region can be attributed to availability of sophisticated healthcare infrastructure and presence of key players in the region.

Below are the leading companies profiled in this Antiviral Drugs Market Report:

  
Abbott Laboratories
  
AbbVie Inc.
  
Astra Zeneca AB
  
Aurobindo Pharma
  
Bristol-Myers Squibb Company
  
Cipla Inc.
  
F. Hoffmann-La Roche Ltd.
  
Gilead Sciences Inc.
  
GlaxoSmithKline plc
  
Hoffmann-La Roche AG
  
Johnson & Johnson Services, Inc.
  
Merck & Co. Inc.
  
Novartis International AG
  
Pfizer Inc.
  
Reddys Laboratories Ltd
  
Sanofi

Global Antiviral Drugs Market Segmentation:

By Drug Class

  
DNA Polymerase Inhibitors
  
Reverse Transcriptase Inhibitors
  
Protease Inhibitors
  
Neuraminidase Inhibitors
  
Others

By Type

  
Branded
  
Generic

By Application

  
HIV
  
Hepatitis
  
Herpes
  
Influenza
  
Others
This research comprehensively answers the following 9 important questions:

  
Q.1. What are some of the most promising growth trends in the Antiviral Drugs market worldwide?
  
Q.2.Which segments and sub-segments will grow at a faster pace and why? Which segment is nearing the peak and demand saturation?
  
Q.3.Which region will witness a higher growth rate and why? Which region might see a slower or negative growth region?
  
Q.4.What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Antiviral Drugs market?
  
Q.5.What are the business risks and who pose challenges to the global leaders and are competitive threats in this Antiviral Drugs market?
  
Q.6.What are the emerging trends post COVID-19 reshuffle in this Antiviral Drugs market and the what are reasons behind these trends and do they translate in global exploration?
  
Q.7. Who are the major global and regional players in the Antiviral Drugs market? Which are the strategic initiatives key players are pursuing for business growth?
  
Q.8.Which are the competing products in Antiviral Drugs market and how big of a threat do they pose for loss of market share by material or product substitution?
  
Q.9.What M & A activity has occurred in the last 5 years and what is its impact on the Antiviral Drugs industry?